BioNTech price target lowered to $130 from $145 at TD Cowen

TD Cowen lowered the firm’s price target on BioNTech to $130 from $145 and keeps a Market Perform rating on the shares. The analyst noted its Covid vaccine sales beat estimates but its Comirnaty guidance was light. Also, its oncology pipeline progressing but slower than expected.